TLR4 and mantle cell lymphoma: LPS-pretreated TLR4-positive/myeloid differentiation 88 (MyD88)-positive mantle cell lymphoma(MCL) inhibited the proliferation and cytolytic activity of T cells by secreted IL-10 and VEGF, and triggers a cascade that leads to MCL growth and evasion from immune surveillance [29].